Prasugrel, a Platelet P2Y12 Receptor Antagonist, Improves Abnormal Gait in a Novel Murine Model of Thrombotic Hindlimb Ischemia
BackgroundThe efficacy of P2Y12 inhibition for the prevention of cardiovascular events in patients with peripheral arterial disease (PAD) has been established. However, the therapeutic effects on ischemic limb complications are less clear. Accordingly, we aimed to develop a novel murine model of thr...
Main Authors: | Kousaku Ohno, Atsuyuki Tomizawa, Makoto Mizuno, Joseph A. Jakubowski, Atsuhiro Sugidachi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-04-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.115.002889 |
Similar Items
-
Prasugrel and Acquired Thrombotic Thrombocytopenic Purpura Associated with ADAMTS13 Activity Deficiency
by: Yanet Parodis Lopez, et al.
Published: (2016-07-01) -
A Novel Model of Intravital Platelet Imaging Using CD41-ZsGreen1 Transgenic Rats.
by: Makoto Mizuno, et al.
Published: (2016-01-01) -
Prasugrel
by: Gianluca Airoldi, et al.
Published: (2013-04-01) -
Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview
by: Hillegass B
Published: (2011-07-01) -
Prasugrel Inappropriate Use in Patients Post-percutaneous coronary intervention (PCI). A Single Center Study
by: Ahmed Amro, et al.
Published: (2019-07-01)